STAT May 22, 2024
Jenna Phillips

Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs are coming to market faster than ever. A 2024 analysis of drugs included in this program showed they had 23% shorter clinical development timelines than those that were not part of the program, with no negative effects on their safety profiles. This regulatory innovation is great for patients, pharmaceutical companies, health care providers, and the full health care landscape, getting new medicines to the people who need them in ever-shorter time.

Using real-world data to monitor drug safety and effectiveness adds an important capability to identify ways to improve patient and clinician experiences with a drug, based on side effects, adverse events, prescribing patterns, and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Medical Devices, Pharma, Pharma / Biotech, Survey / Study, Trends
Related Articles:
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More
Pharma Pulse 11/25/24: Deepening Patient Relationships,
Halozyme abandons its €2bn pursuit of Evotec
BridgeBio poised to challenge Pfizer after Attruby approval
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy

Share This Article